New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis

Drugs

Volumn 71, Issue 8, 2011, Pages 981-1001

  Ding, Qiang ^a   Luckhardt, Tracy ^a   Hecker, Louise ^a   Zhou, Yong ^a   Liu, Gang ^a   Antony, Veena B ^a   DeAndrade, Joao ^a   Thannickal, Victor J ^a  

^a and Clinical Center   (United States)

Author keywords

Acetylcysteine; Anticoagulants; Azathioprine; Bosentan; Corticosteroids; Etanercept; Idiopathic pulmonary fibrosis; Imatinib; Interferon; Interferon gamma; Oxygen; Pirfenidone; Prednisone; Sildenafil.

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACETYLCYSTEINE; ANTICOAGULANT AGENT; ANTIOXIDANT; AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; ETANERCEPT; FASUDIL; GAMMA1B INTERFERON; IMATINIB; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; MICRORNA; PIRFENIDONE; PLACEBO; PREDNISONE; PROTEIN KINASE INHIBITOR; RHO KINASE INHIBITOR; SILDENAFIL; SLX 2119; UNCLASSIFIED DRUG; WARFARIN;

AGING; CELL AGING; CELL HETEROGENEITY; CELL TRANSFORMATION; CELLULAR PLASTICITY; CIGARETTE SMOKING; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG TARGETING; DRUG WITHDRAWAL; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIAL MESENCHYMAL TRANSITION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; GLOMERULOSCLEROSIS; HOMEOSTASIS; HUMAN; HYPERTENSIVE GLOMERULOSCLEROSIS; HYPOXEMIA; INHALATION; INTESTINAL FIBROSIS; KIDNEY FIBROSIS; LIVER FIBROSIS; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG PARENCHYMA; MECHANOTRANSDUCTION; MONOTHERAPY; MYOFIBROBLAST; NONHUMAN; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; OXYGEN THERAPY; PATHOGENESIS; PLASTICITY; PULMONARY REHABILITATION; QUALITY OF LIFE; REVIEW; RISK FACTOR; SENESCENCE; SLEEP DISORDERED BREATHING; TUBULOINTERSTITIAL KIDNEY FRIBOSIS; VIRUS INFECTION;

ANIMALS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MOLECULAR TARGETED THERAPY; RISK FACTORS;

EID: 79958788032     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11591490-000000000-00000     Document Type: Review

References (188)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165 (2): 277-304.
2. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174 (7): 810-6. (Pubitemid 44511663)
3. Chailleux E, Fauroux B, Binet F, et al. Predictors of survival in patients receiving domiciliary oxygen therapy or mechanical ventilation: a 10-year analysis of ANTADIR Observatory. Chest 1996; 109 (3): 741-9. (Pubitemid 26086943)
4. Tzanakis N, Samiou M, Lambiri I, et al. Evaluation of healthrelated quality-of-life and dyspnea scales in patients with idiopathic pulmonary fibrosis: correlation with pulmonary function tests. Eur J Intern Med 2005; 16 (2): 105-12. (Pubitemid 40523053)
5. Harris-Eze AO, Sridhar G, Clemens RE, et al. Oxygen improves maximal exercise performance in interstitial lung disease. Am J Respir Crit Care Med 1994; 150 (6 Pt 1): 1616-22. (Pubitemid 24361736)
6. Madison JM, Irwin RS. Chronic cough in adults with interstitial lung disease. Curr Opin Pulm Med 2005; 11 (5): 412-6. (Pubitemid 41291085)
7. Tobin RW, Pope 2nd CE, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158 (6): 1804-8. (Pubitemid 29008818)
8. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 27 (1): 136-42. (Pubitemid 43092677)
9. Raghu G, Yang ST, Spada C, et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006; 129 (3): 794-800.
10. Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009; 136 (3): 772-8.
11. Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 2008; 178 (12): 1257-61.
12. Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med 2010; 104 (7): 1035-41.
13. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129 (3): 746-52.
14. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128 (4): 2393-9. (Pubitemid 41507585)
15. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161 (2 Pt 1): 646-64.
16. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350 (2): 125-33. (Pubitemid 38056223)
17. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo- controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171 (9): 1040-7. (Pubitemid 40616955)
18. DemedtsM, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis.NEngl JMed 2005; 353 (21): 2229-42. (Pubitemid 41697286)
19. Kubo H, Nakayama K,YanaiM, et al.Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128 (3): 1475-82. (Pubitemid 41324435)
20. King Jr TE, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177 (1): 75-81.
21. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178 (9): 948-55.
22. King Jr TE, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374 (9685): 222-8.
23. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo- controlled trial results. Am J Respir Crit Care Med 2010; 181 (6): 604-10.
24. Noble PW, Albera C, Bradford WZ, et al., for the CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. Epub 2011 May 13.
25. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35 (4): 821-9.
26. Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363 (7): 620-8.
27. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005; 142 (12 Pt 1): 963-7.
28. National Heart, Lung, and Blood Institute (NHLBI). Anticoagulant effectiveness in idiopathic pulmonary fibrosis (ACE-IPF) [ClinicalTrials.gov identifier NCT00957242]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 May 25].
29. InterMune. Three-arm study of the safety and efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis [ClinicalTrials.gov identifier NCT00287716]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 May 25].
30. InterMune. Safety and efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis [ClinicalTrials.gov identifier NCT00287729]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 May 25].
31. Pulmonary-Allergy Drugs Advisory Committee. Pirfenidone NDA 22-535 [online]. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/ UCM206399.pdf [Accessed 2011 May 25].
32. Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ 1990; 301 (6759): 1015-7. (Pubitemid 20381075)
33. Hubbard R, Lewis S, Richards K, et al. Occupational exposure tometal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996; 347 (8997): 284-9. (Pubitemid 26041039)
34. Iwai K, Mori T, Yamada N, et al. Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med 1994; 150 (3): 670-5. (Pubitemid 24291493)
35. Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Am J Epidemiol 2000; 152 (4): 307-15. (Pubitemid 30626724)
36. Miyake Y, Sasaki S, Yokoyama T, et al. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. Ann Occup Hyg 2005; 49 (3): 259-65. (Pubitemid 40547331)
37. PinheiroGA, Antao VC,Wood JM, et al. Occupational risks for idiopathic pulmonary fibrosis mortality in the United States. Int J Occup Environ Health 2008; 14 (2): 117-23. (Pubitemid 351671416)
38. Gustafson T, Dahlman-Hoglund A, Nilsson K, et al. Occupational exposure and severe pulmonary fibrosis. Respir Med 2007; 101 (10): 2207-12. (Pubitemid 47324247)
39. Mullen J, Hodgson MJ, DeGraff CA, et al. Case-control study of idiopathic pulmonary fibrosis and environmental exposures. J Occup Environ Med 1998; 40 (4): 363-7. (Pubitemid 28180813)
40. Kitamura H, Ichinose S, Hosoya T, et al. Inhalation of inorganic particles as a risk factor for idiopathic pulmonary fibrosis: elemental microanalysis of pulmonary lymph nodes obtained at autopsy cases. Pathol Res Pract 2007; 203 (8): 575-85. (Pubitemid 47163498)
41. Enomoto T, Usuki J, Azuma A, et al. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest 2003; 123 (6): 2007-11. (Pubitemid 36706726)
42. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005; 172 (9): 1146-52. (Pubitemid 43066651)
43. Taskar VS, Coultas DB. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc 2006; 3 (4): 293-8. (Pubitemid 43845405)
44. Garcia-Sancho Figueroa MC, Carrillo G, Perez-Padilla R, et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population: a case-control study. Respir Med 2010; 104 (2): 305-9.
45. Antoniou KM, Hansell DM, Rubens MB, et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med 2008; 177 (2): 190-4.
46. King Jr TE, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164 (7): 1171-81. (Pubitemid 33052246)
47. Sweet MP, Patti MG, Leard LE, et al. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J Thorac Cardiovasc Surg 2007; 133 (4): 1078-84. (Pubitemid 46435907)
48. Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med 2009; 103 (6): 927-31.
49. Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009; 179 (5): 408-13.
50. D'Ovidio F, Singer LG, Hadjiliadis D, et al. Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. Ann Thorac Surg 2005; 80 (4): 1254-60. (Pubitemid 41354098)
51. FortunatoGA, Machado MM, Andrade CF, et al. Prevalence of gastroesophageal reflux in lung transplant candidates with advanced lung disease. J Bras Pneumol 2008; 34 (10): 772-8.
52. Matsuse T, Ohga E, Teramoto S, et al. Immunohistochemical localisation of advanced glycation end products in pulmonary fibrosis. J Clin Pathol 1998; 51 (7): 515-9. (Pubitemid 28375031)
53. Chen L, Wang T, Wang X, et al. Blockade of advanced glycation end product formation attenuates bleomycininduced pulmonary fibrosis in rats. Respir Res 2009; 10: 55.
54. Englert JM, Hanford LE, Kaminski N, et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 2008; 172 (3): 583-91. (Pubitemid 351354532)
55. Queisser MA, Kouri FM, Konigshoff M, et al. Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types. Am J Respir Cell Mol Biol 2008; 39 (3): 337-45.
56. Kelly BG, Lok SS, Hasleton PS, et al. A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 166 (4): 510-3.
57. Lok SS, Stewart JP, Kelly BG, et al. Epstein-Barr virus and wild p53 in idiopathic pulmonary fibrosis. Respir Med 2001; 95 (10): 787-91. (Pubitemid 33019572)
58. Stewart JP, Egan JJ, Ross AJ, et al. The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1999; 159 (4 Pt 1): 1336-41. (Pubitemid 29202576)
59. Tang YW, Johnson JE, Browning PJ, et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol 2003; 41 (6): 2633-40. (Pubitemid 36712478)
60. Lawson WE, Crossno PF, Polosukhin VV, et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol 2008; 294 (6): L1119-26.
61. Hayakawa H, Shirai M, Uchiyama H, et al. Lack of evidence for a role of Epstein-Barr virus in the increase of lung cancer in idiopathic pulmonary fibrosis. Respir Med 2003; 97 (3): 281-4. (Pubitemid 36266885)
62. Zamo A, Poletti V, Reghellin D, et al. HHV-8 and EBV are not commonly found in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 (2): 123-8. (Pubitemid 41020017)
63. Mora AL, Woods CR, Garcia A, et al. Lung infection with gamma-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice. Am J Physiol Lung Cell Mol Physiol 2005; 289 (5): L711-21. (Pubitemid 41504401)
64. McMillan TR, Moore BB, Weinberg JB, et al. Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus. Am J Respir Crit Care Med 2008; 177 (7): 771-80. (Pubitemid 351490564)
65. Bitterman PB, Adelberg S, Crystal RG. Mechanisms of pulmonary fibrosis: spontaneous release of the alveolar macrophage-derived growth factor in the interstitial lung disorders. J Clin Invest 1983; 72 (5): 1801-13. (Pubitemid 14229060)
66. SelmanM,King TE, PardoA. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann InternMed 2001; 134 (2): 136-51. (Pubitemid 32096342)
67. Araki T, Katsura H, Sawabe M, et al. A clinical study of idiopathic pulmonary fibrosis based on autopsy studies in elderly patients. Intern Med 2003; 42 (6): 483-9. (Pubitemid 36926809)
68. Armanios M, Alder JK, Parry EM, et al. Short telomeres are sufficient to cause the degenerative defects associated with aging. Am J Hum Genet 2009; 85 (6): 823-32.
69. Blasco MA. Telomere length, stem cells and aging. Nat Chem Biol 2007; 3 (10): 640-9. (Pubitemid 47417712)
70. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007; 104 (18): 7552-7. (Pubitemid 47185944)
71. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008; 105 (35): 13051-6.
72. Cronkhite JT, Xing C, RaghuG, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178 (7): 729-37.
73. Thannickal VJ, Loyd JE. Idiopathic pulmonary fibrosis: a disorder of lung regeneration?Am J Respir Crit Care Med 2008; 178 (7): 663-5.
74. Matulionis DH. Chronic cigarette smoke inhalation and aging in mice: 1, morphologic and functional lung abnormalities. Exp Lung Res 1984; 7 (3-4): 237-56. (Pubitemid 15173751)
75. Kinnula VL, Fattman CL, Tan RJ, et al. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005; 172 (4): 417-22. (Pubitemid 41117386)
76. Brenner DA. Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 2009; 120: 361-8.
77. Kuwano K, Kunitake R, Kawasaki M, et al. P21Waf1/ Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1996; 154 (2 Pt 1): 477-83. (Pubitemid 26269122)
78. Montuschi P, Ciabattoni G, Paredi P, et al. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998; 158 (5 Pt 1): 1524-7.
79. Kuwano K, Nakashima N, Inoshima I, et al. Oxidative stress in lung epithelial cells from patients with idiopathic interstitial pneumonias. Eur Respir J 2003; 21 (2): 232-40. (Pubitemid 36204536)
80. Lambeth JD. Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 2007; 43 (3): 332-47. (Pubitemid 46992767)
81. Dasari A, Bartholomew JN, Volonte D, et al. Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogenactivated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res 2006; 66 (22): 10805-14. (Pubitemid 44876976)
82. MacNee W. Accelerated lung aging: a novel pathogenic mechanism of chronic obstructive pulmonary disease (COPD). Biochem Soc Trans 2009; 37 (Pt 4): 819-23.
83. Wang E. Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. Cancer Res 1995; 55 (11): 2284-92.
84. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8 (9): 729-40. (Pubitemid 47312822)
85. Toussaint O, Medrano EE, von Zglinicki T. Cellular and molecular mechanisms of stress-induced premature senescence (SIPS) of human diploid fibroblasts and melanocytes. Exp Gerontol 2000; 35 (8): 927-45.
86. Waghray M, Cui Z, Horowitz JC, et al. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J 2005; 19 (7): 854-6. (Pubitemid 40617407)
87. Larios JM, Budhiraja R, Fanburg BL, et al. Oxidative protein cross-linking reactions involving L-tyrosine in transforming growth factor-beta1-stimulated fibroblasts. J Biol Chem 2001; 276 (20): 17437-41.
88. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. JClin Invest 2005; 115 (10): 2656-64. (Pubitemid 41434389)
89. Korfei M, Ruppert C, Mahavadi P, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178 (8): 838-46.
90. Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007; 293 (3): L525-34. (Pubitemid 47358808)
91. Willis BC, Liebler JM, Luby-Phelps K, et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005; 166 (5): 1321-32. (Pubitemid 40586504)
92. Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006; 103 (35): 13180-5. (Pubitemid 44338936)
93. Tanjore H, Xu XC, Polosukhin VV, et al. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med 2009; 180 (7): 657-65.
94. Chilosi M, Poletti V, Zamo A, et al. Aberrant Wnt/betacatenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003; 162 (5): 1495-502. (Pubitemid 36512831)
95. Chilosi M, Zamo A, Doglioni C, et al. Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis. Respir Res 2006; 7: 95.
96. Hashimoto N, Phan SH, Imaizumi K, et al. Endothelialmesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2009; 43 (2): 161-72.
97. Burns AR, Smith CW, Walker DC. Unique structural features that influence neutrophil emigration into the lung. Physiol Rev 2003; 83 (2): 309-36. (Pubitemid 36378675)
98. Sirianni FE, Milaninezhad A, Chu FS, et al. Alteration of fibroblast architecture and loss of Basal lamina apertures in human emphysematous lung. Am J Respir Crit Care Med 2006; 173 (6): 632-8. (Pubitemid 43363804)
99. Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170 (6): 1807-16. (Pubitemid 47339255)
100. Hagood JS, Prabhakaran P, Kumbla P, et al. Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis. Am J Pathol 2005; 167 (2): 365-79. (Pubitemid 43026094)
101. Zhou Y, Hagood JS, Murphy-Ullrich JE. Thy-1 expression regulates the ability of rat lung fibroblasts to activate transforming growth factor-beta in response to fibrogenic stimuli. Am J Pathol 2004; 165 (2): 659-69. (Pubitemid 38971395)
102. Rege TA, Hagood JS. Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses. Biochim Biophys Acta 2006; 1763 (10): 991-9. (Pubitemid 44466122)
103. Zhou Y, Koli K, Hagood JS, et al. Latent transforming growth factor-beta-binding protein-4 regulates transforming growth factor-beta1 bioavailability for activation by fibrogenic lung fibroblasts in response to bleomycin. Am J Pathol 2009; 174 (1): 21-33.
104. Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan micro- RNAs. Nat Rev Genet 2004; 5 (5): 396-400. (Pubitemid 38529411)
105. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation ofmicroRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105 (35): 13027-32.
106. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456 (7224): 980-4.
107. Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2010; 182 (2): 220-9.
108. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207 (8): 1589-97.
109. Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-betainduced collagen expression via inhibition of E-box repressors. Proc Natl Acad SciUS A 2007; 104 (9): 3432-7. (Pubitemid 46364176)
110. Shan H, Zhang Y, Lu Y, et al. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res 2009; 83 (3): 465-72.
111. Duisters RF, Tijsen AJ, Schroen B, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009; 104 (2): 170-8, 6p following 178.
112. Cushing L, Kuang PP, Qian J, et al. MIR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol. Epub 2010 Oct 22.
113. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010; 11 (2): 141-7.
114. Cheng Y, Zhu P, Yang J, et al. Ischaemic preconditioningregulated miR-21 protects heart against ischaemia/ reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc Res 2010; 87 (3): 431-9.
115. Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010; 18 (3): 282-93.
116. Roy S, Khanna S, Hussain SR, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009; 82 (1): 21-9.
117. Kato M, Putta S, Wang M, et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009; 11 (7): 881-9.
118. Shan SW, Lee DY, Deng Z, et al. MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nat Cell Biol 2009; 11 (8): 1031-8.
119. Cordes KR, Sheehy NT, White MP, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009; 460 (7256): 705-10.
120. Pottier N, Maurin T, Chevalier B, et al. Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions. PLoS One 2009; 4 (8): e6718.
121. Martin MM, Lee EJ, Buckenberger JA, et al. MicroRNA- 155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 2006; 281 (27): 18277-84. (Pubitemid 44035484)
122. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10 (5): 593-601. (Pubitemid 351627379)
123. Park SM, Gaur AB, Lengyel E, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22 (7): 894-907. (Pubitemid 351482843)
124. Korpal M, Lee ES, Hu G, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283 (22): 14910-4.
125. Puklin-Faucher E, Sheetz MP. The mechanical integrin cycle. J Cell Sci 2009; 122 (Pt 2): 179-86.
126. Wipff PJ, Rifkin DB, Meister JJ, et al. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol 2007; 179 (6): 1311-23. (Pubitemid 350277747)
127. Dubois CM, Laprise MH, Blanchette F, et al. Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 1995; 270 (18): 10618-24.
128. Lawrence DA, Pircher R, Kryceve-Martinerie C, et al. Normal embryo fibroblasts release transforming growth factors in a latent form. J Cell Physiol 1984; 121 (1): 184-8. (Pubitemid 14017248)
129. Lawrence DA, Pircher R, Jullien P. Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions. Biochem Biophys Res Commun 1985; 133 (3): 1026-34. (Pubitemid 16142882)
130. Koli K, Saharinen J, Karkkainen M, et al. Novel non- TGF-beta-binding splice variant of LTBP-4 in human cells and tissues provides means to decrease TGF-beta deposition. J Cell Sci 2001; 114 (Pt 15): 2869-78. (Pubitemid 32785465)
131. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003; 116 (Pt 2): 217-24. (Pubitemid 36163863)
132. Hyytiainen M, Penttinen C, Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci 2004; 41 (3): 233-64. (Pubitemid 38888060)
133. Koli K, Wempe F, Sterner-Kock A, et al. Disruption of LTBP-4 function reduces TGF-beta activation and enhances BMP-4 signaling in the lung. J Cell Biol 2004; 167 (1): 123-33. (Pubitemid 39363420)
134. Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96 (3): 319-28. (Pubitemid 29077586)
135. Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100 (4): 768-76. (Pubitemid 27371693)
136. Yehualaeshet T, O'Connor R, Green-Johnson J, et al. Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. Am J Pathol 1999; 155 (3): 841-51. (Pubitemid 29426830)
137. Gauldie J, Bonniaud P, Sime P, et al. TGF-beta, Smad3 and the process of progressive fibrosis. Biochem Soc Trans 2007; 35 (Pt 4): 661-4. (Pubitemid 47310335)
138. Khalil N, O'Connor RN, Unruh HW, et al. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991; 5 (2): 155-62.
139. Pohlers D, Brenmoehl J, Loffler I, et al. TGF-beta and fibrosis in different organs: molecular pathway imprints. Biochim Biophys Acta 2009; 1792 (8): 746-56.
140. Roberts AB, Tian F, Byfield SD, et al. Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006; 17 (1-2): 19-27. (Pubitemid 43117513)
141. Ahamed J, Burg N, Yoshinaga K, et al. In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-beta1. Blood 2008; 112 (9): 3650-60.
142. Ahamed J, Janczak CA, Wittkowski KM, et al. In vitro and in vivo evidence that thrombospondin-1 (TSP-1) contributes to stirring- and shear-dependent activation of platelet-derived TGF-beta1. PLoS One 2009; 4 (8): e6608.
143. Saharinen J, Taipale J, Keski-Oja J. Association of the small latent transforming growth factor-beta with an eight cysteine repeat of its binding protein LTBP-1. EMBO J 1996; 15 (2): 245-53. (Pubitemid 26029204)
144. Unsold C, Hyytiainen M, Bruckner-Tuderman L, et al. Latent TGF-beta binding protein LTBP-1 contains three potential extracellular matrix interacting domains. J Cell Sci 2001; 114 (Pt 1): 187-97. (Pubitemid 32118068)
145. Isogai Z, Ono RN, Ushiro S, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003; 278 (4): 2750-7. (Pubitemid 36801356)
146. Jenkins RG, Su X, Su G, et al. Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest 2006; 116 (6): 1606-14.
147. Sheppard D. Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev 2005; 24 (3): 395-402. (Pubitemid 41569979)
148. Zhou Y, Hagood JS, Lu B, et al. Thy-1-integrin alpha v beta5 interactions inhibit lung fibroblast contractioninduced latent transforming growth factor-beta1 activation and myofibroblast differentiation. J Biol Chem 2010; 285 (29): 22382-93.
149. Parsons JT, Slack-Davis J, Tilghman R, et al. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res 2008; 14 (3): 627-32. (Pubitemid 351231140)
150. Thannickal VJ, Lee DY, White ES, et al. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem 2003; 278 (14): 12384-9. (Pubitemid 36800223)
151. Ding Q, Gladson CL, Wu H, et al. Focal adhesion kinase (FAK)-related non-kinase inhibits myofibroblast differentiation through differential MAPK activation in a FAK-dependent manner. J Biol Chem 2008; 283 (40): 26839-49.
152. Cai GQ, Zheng A, Tang Q, et al. Downregulation of FAKrelated non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts. Exp Cell Res 2010; 316 (9): 1600-9.
153. Horowitz JC, Rogers DS, Sharma V, et al. Combinatorial activation of FAK and AKT by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal 2007; 19 (4): 761-71. (Pubitemid 46290691)
154. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci 2003; 116 (Pt 8): 1409-16. (Pubitemid 36527488)
155. Skhirtladze C, Distler O, Dees C, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008; 58 (5): 1475-84. (Pubitemid 351705937)
156. Garneau-Tsodikova S, Thannickal VJ. Protein kinase inhibitors in the treatment of pulmonary fibrosis. Curr Med Chem 2008; 15 (25): 2632-40.
157. Kutz SM, Hordines J, McKeown-Longo PJ, et al. TGFbeta1- induced PAI-1 gene expression requires MEK activity and cell-to-substrate adhesion. J Cell Sci 2001; 114 (Pt 21): 3905-14. (Pubitemid 33094705)
158. Mulder KM. Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Factor Rev 2000; 11 (1-2): 23-35. (Pubitemid 30169723)
159. Roelen BA, Cohen OS, Raychowdhury MK, et al. Phosphorylation of threonine 276 in Smad4 is involved in transforming growth factor-beta-induced nuclear accumulation. Am J Physiol Cell Physiol 2003; 285 (4): C823-30. (Pubitemid 37158807)
160. Furukawa F, Matsuzaki K, Mori S, et al. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 2003; 38 (4): 879-89. (Pubitemid 37221671)
161. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327 (5962): 198-201.
162. Ponomarev ED, Veremeyko T, Barteneva N, et al. Micro- RNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha- PU.1 pathway. Nat Med 2010; 17 (1): 64-70.
163. Cheng Y, Liu X, Yang J, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009; 105 (2): 158-66.
164. Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3 (5): 349-63. (Pubitemid 34619269)
165. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rhokinase). Science 1996; 273 (5272): 245-8. (Pubitemid 26285892)
166. Kawano Y, Fukata Y, Oshiro N, et al. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell Biol 1999; 147 (5): 1023-38.
167. Nishikimi T, Matsuoka H. Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis. J Pharmacol Sci 2006; 100 (1): 22-8. (Pubitemid 43161610)
168. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 2007; 50 (1): 17-24. (Pubitemid 47220442)
169. Oka M, Fagan KA, Jones PL, et al. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008; 155 (4): 444-54.
170. Schaafsma D, Gosens R, Zaagsma J, et al. Rho kinase inhibitors: a novel therapeutical intervention in asthma? Eur J Pharmacol 2008; 585 (2-3): 398-406.
171. Nagatoya K, Moriyama T, Kawada N, et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002; 61 (5): 1684-95. (Pubitemid 34437922)
172. Murata T, Arii S, Nakamura T, et al. Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells. J Hepatol 2001; 35 (4): 474-81. (Pubitemid 32964446)
173. Nishikimi T, Akimoto K, Wang X, et al. Fasudil, a Rhokinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 2004; 22 (9): 1787-96. (Pubitemid 39141972)
174. Boerma M, Fu Q, Wang J, et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul Fibrinolysis 2008; 19 (7): 709-18.
175. Hinz B, Dugina V, Ballestrem C, et al. Alpha-smooth muscle actin is crucial for focal adhesion maturation in myofibroblasts. Mol Biol Cell 2003; 14 (6): 2508-19. (Pubitemid 36724338)
176. Hinz B, Gabbiani G, Chaponnier C. The NH2-terminal peptide of alpha-smooth muscle actin inhibits force generation by the myofibroblast in vitro and in vivo. J Cell Biol 2002; 157 (4): 657-63. (Pubitemid 34839793)
177. Cantin AM, North SL, Fells GA, et al. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 1987; 79 (6): 1665-73. (Pubitemid 17117272)
178. Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. AmRev Respir Dis 1989; 139 (2): 370-2. (Pubitemid 19057410)
179. National Heart, Lung, and Blood Institute (NHLBI). Evaluating the effectiveness of prednisone, azathioprine, and N-acetylcysteine in people with idiopathic pulmonary fibrosis (PANTHER-IPF) [ClinicalTrials.gov identifier NCT00650091]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2011 May 25].
180. Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009; 15 (9): 1077-81.
181. Abrahams E, Silver M. The case for personalized medicine. J Diabetes Sci Technol 2009; 3 (4): 680-4.
182. Aquino-Galvez A, Perez-Rodriguez M, Camarena A, et al. MICA polymorphisms and decreased expression of the MICAreceptorNKG2Dcontribute to idiopathic pulmonary fibrosis susceptibility. Hum Genet 2009; 125 (5-6): 639-48.
183. Checa M, Ruiz V, Montano M, et al. MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum Genet 2008; 124 (5): 465-72.
184. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008; 5 (4): e93.
185. Daniil ZD, Papageorgiou E,KoutsokeraA, et al. Serumlevels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis. PulmPharmacol Ther 2008; 21 (1): 26-31.
186. Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 2009; 135 (6): 1557-63.
187. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179 (8): 717-23.
188. Xaubet A, Marin-Arguedas A, Lario S, et al. Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168 (4): 431-35 (Pubitemid 37046871)